Cargando…

Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model

Background: The pharmacokinetic/pharmacodynamic (PK/PD) index of carbapenems that best correlates with in vivo antimicrobial activity is percent time of dosing interval in which free drug concentration remains above MIC (%fT > MIC), while the magnitudes of the PK/PD index of carbapenems remains u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yan, Liu, Lanyu, Wu, Qiping, Yin, Qiufen, Xie, Feifan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686672/ https://www.ncbi.nlm.nih.gov/pubmed/36421304 http://dx.doi.org/10.3390/antibiotics11111660

Ejemplares similares

Meropenem PK/PD Variability and Renal Function: “We Go Together”
por: Angelini, Jacopo, et al.
Publicado: (2023)

Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data
por: Zyryanov, Sergey, et al.
Publicado: (2023)

2560. Individual Meropenem Epithelial Lining Fluid and Plasma PK/PD Target Attainment in Patients with Pneumonia
por: Rohani, Roxane, et al.
Publicado: (2023)

A prospective, observational study comparing the PK/PD relationships of generic Meropenem (Mercide(®)) to the innovator brand in critically ill patients
por: Mer, Mervyn, et al.
Publicado: (2016)

Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
por: Heil, Emily, et al.
Publicado: (2017)

1676. PK, Safety and Tolerability of VABOMERE(®) (meropenem-vaborbactam) in Infants, Children and Adolescents
por: Bokesch, Paula M, et al.
Publicado: (2023)

Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer
por: Yao, Qing-yu, et al.
Publicado: (2019)

2953. PK/PD Comparison of a New Dosing Scheme for Meropenem Adapted to Outpatient Parenteral Antimicrobial Therapy (OPAT) in Non-Critically-Ill Patients
por: Briquet, Caroline, et al.
Publicado: (2023)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
por: Heemskerk, Hans, et al.
Publicado: (2010)

Population Pharmacokinetic Model of the Pregabalin-Sildenafil Interaction in Rats: Application of Simulation to Preclinical PK-PD Study Design
por: Bender, Gregor, et al.
Publicado: (2009)

PK-PD correlation of anti-infective agents for dose adjustment in one severe burn child with sepsis
por: Campos, EV, et al.
Publicado: (2011)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)
por: Le, Jennifer, et al.
Publicado: (2023)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections
por: Lai, Chih-Cheng, et al.
Publicado: (2019)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023)

The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum
por: Zhang, Nan, et al.
Publicado: (2016)

The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2021)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients
por: Chen, Di, et al.
Publicado: (2023)

Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study
por: Cao, Guangna, et al.
Publicado: (2022)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach
por: Maguigan, Kelly L., et al.
Publicado: (2021)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration
por: Akashita, Gaku, et al.
Publicado: (2015)

PK-PD Analysis of Marbofloxacin against Streptococcus suis in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

The PK/PD Integration and Resistance of Tilmicosin against Mycoplasma hyopneumoniae
por: Huang, Zilong, et al.
Publicado: (2020)

S17.3 PK/PD in the treatment of hospital-acquired pneumonia
Publicado: (2005)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia
por: Zhou, Yingjie, et al.
Publicado: (2022)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
por: Sou, Tomás, et al.
Publicado: (2020)

Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation
por: Song, Xiangqing, et al.
Publicado: (2019)

Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial
por: Zhang, Wantong, et al.
Publicado: (2018)

Prediction of Clinical Irrelevance of PK Differences in Atorvastatin Using PK/PD Models Derived From Literature-Based Meta-Analyses
por: Vargo, R, et al.
Publicado: (2014)

1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
por: Ghahramani, Parviz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pskoukilc694785u87ov15qc9l